Hallux Valgus, also known as Bunion, is the most common forefoot problem in adults. It is the most common pathologic entity of the big toe. It refers to the progressive swelling of the soft tissue. It is observed that worldwide, Hallux valgus has been reported to affect approximately 23% of the adult population aged 18 to 65 years.
The total Hallux Valgus prevalent cases are estimated to be around 180,658,286 in the 7MM (the U.S., EU5, and Japan) in 2020 and among all 7MM, the United States accounted for nearly 41% of the total prevalent cases of Hallux Valgus. Moreover, it is observed that the condition is more prevalent in women than in men. It could be due to the choice of footwear as wearing narrow-toed shoes, and high heels are known to exacerbate the problem; thus bunions are more common in women.
Hallux Valgus lacks novel and sophisticated technologies in the pipeline. According to the market analysis, Hallux Valgus market size in the 7MM is expected to rise during the study period (2018–2030), at a CAGR of 1.7%.
Today, a few pharmaceutical and biotech companies are developing pain relief medications for post-surgical bunionectomy pain relief. Companies like Concentric Analgesics, Taiwan Liposome Company, Ipsen and others are the key players for pain relief and are not focusing on the actual underlying cause. However, medicines such as NSAIDs and other analgesics are abundantly available in the market for pain relief.
Source: Hallux Valgus Treatment Market Size and Trends Analysis